CRNX stock touches 52-week low at $35.47 amid market shifts
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) stock has reached a 52-week low, trading at $35.47, with InvestingPro technical indicators showing oversold conditions. The stock has declined sharply, ...
TD Cowen initiates Crinetics stock with Buy rating, sees high potential
TD Cowen began coverage of Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating, citing the company's strong position in ...
Tempo4d
Free Health Check Program: List of Available Screenings
To access the free health screening, people only need to register through the SATUSEHAT Mobile (SSM) application. Following ...
Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified ...
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation ...
FiercePharma5d
With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...